{'52WeekChange': 0.008340478,
 'SandP52WeekChange': 0.0644362,
 'address1': '100 Corporate Court',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 47.11,
 'askSize': 900,
 'averageDailyVolume10Day': 896425,
 'averageVolume': 713055,
 'averageVolume10days': 896425,
 'beta': 1.397759,
 'beta3Year': None,
 'bid': 47.08,
 'bidSize': 800,
 'bookValue': 8.425,
 'category': None,
 'circulatingSupply': None,
 'city': 'South Plainfield',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 47.975,
 'dayLow': 46.34,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -13.337,
 'enterpriseToRevenue': 8.399,
 'enterpriseValue': 2701523968,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '908 222 7231',
 'fiftyDayAverage': 51.959858,
 'fiftyTwoWeekHigh': 59.89,
 'fiftyTwoWeekLow': 30.792,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 57492632,
 'forwardEps': -2.47,
 'forwardPE': -19.08907,
 'fromCurrency': None,
 'fullTimeEmployees': 754,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.0321,
 'heldPercentInstitutions': 0.99316,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/ptcbio.com',
 'longBusinessSummary': 'PTC Therapeutics, Inc., a biopharmaceutical company, '
                        'focuses on the discovery, development, and '
                        'commercialization of medicines for the treatment of '
                        'rare disorders. The company offers Translarna '
                        '(ataluren) and Emflaza (deflazacort) for the '
                        'treatment of nonsense mutation Duchenne muscular '
                        'dystrophy in ambulatory patients. It is developing '
                        'Translarna, which is in Phase 2 clinical study for '
                        'the treatment of nonsense mutation aniridia and '
                        'nonsense mutation Dravet syndrome/CDKL5; and RG7916 '
                        'and RO7034067 for the treatment of patients with '
                        'spinal muscular atrophy, as well as PTC596 and '
                        'PTC299, a small molecule dihydrooratate dehydrogenase '
                        '(DHODH) inhibitor that inhibits de novo pyrimidine '
                        'nucleotide synthesis, which is in Phase 1 clinical '
                        'development stage to treat cancer patients. The '
                        'company is also developing gene therapy product '
                        'candidate that include PTC-AADC for the treatment of '
                        'Aromatic L-amino acid decarboxylase deficiency. It '
                        'has collaborations with F. Hoffman-La Roche Ltd and '
                        'Hoffman-La Roche Inc., and the Spinal Muscular '
                        'Atrophy Foundation to develop and commercialize '
                        'compounds identified under its spinal muscular '
                        'atrophy sponsored research program; research '
                        'collaboration with Massachusetts General Hospital for '
                        'the treatment of rare genetic disorders resulting '
                        'from pre-mRNA; and Akcea Therapeutics, Inc. to '
                        'commercialize Tegsedi and Waylivra for the treatment '
                        'of rare diseases in Latin America and the Caribbean. '
                        'PTC Therapeutics, Inc. was founded in 1998 and is '
                        'headquartered in South Plainfield, New Jersey.',
 'longName': 'PTC Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 3093002496,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_1006484',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -292150016,
 'nextFiscalYearEnd': 1640908800,
 'open': 47.33,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.93,
 'phone': '908 222 7000',
 'previousClose': 47.82,
 'priceHint': 2,
 'priceToBook': 5.5964394,
 'priceToSalesTrailing12Months': 9.61587,
 'profitMargins': -0.90827006,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 47.975,
 'regularMarketDayLow': 46.34,
 'regularMarketOpen': 47.33,
 'regularMarketPreviousClose': 47.82,
 'regularMarketPrice': 47.33,
 'regularMarketVolume': 695193,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 65599200,
 'sharesPercentSharesOut': 0.0801,
 'sharesShort': 5251580,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4402173,
 'shortName': 'PTC Therapeutics, Inc.',
 'shortPercentOfFloat': 0.082100004,
 'shortRatio': 7.29,
 'startDate': None,
 'state': 'NJ',
 'strikePrice': None,
 'symbol': 'PTCT',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -4.829,
 'twoHundredDayAverage': 50.150505,
 'volume': 695193,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.ptcbio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '07080'}